NXTM Nxstage Medical, Inc.

   By Colin Kellaher 
 

B. Braun Medical Inc. on Thursday said it agreed to buy NxStage Medical Inc.'s (NXTM) bloodlines business in a deal that could help pave the way for Fresenius Medical Care AG's (FME.XE, FMS) $2 billion takeover of NxStage.

B. Braun, part of closely held B. Braun Melsungen AG of Germany, said the deal adds the Streamline bloodline to its dialysis product portfolio.

The Bensalem, Pa., maker of medical products said it expects to complete the acquisition this year, contingent upon the closing of the Fresenius/NxStage deal.

In a filing with the Securities and Exchange Commission, NxStage said it agreed to the divestiture in an effort to gain Federal Trade Commission clearance of the Fresenius deal, which it still expects to close in 2018.

Fresenius in August 2017 agreed to buy NxStage for $30 a share in a deal aimed at boosting its kidney-dialysis business.

NxStage shareholders voted in October to approve the deal, which has also cleared antitrust review in Germany and the U.K. However, the FTC in October requested more information from the companies, extending the antitrust waiting period on the deal.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 19, 2018 13:31 ET (17:31 GMT)

Nxstage Medical (NASDAQ:NXTM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Nxstage Medical (NASDAQ:NXTM)
Historical Stock Chart
From Jul 2023 to Jul 2024